Data from two novel TEAD inhibitors provide the first evidence for the efficacy and safety of targeted treatments in mesothelioma
In early phase studies, IAG933 and VT3989 led to encouraging disease control rates with manageable toxicity
Adjuvant ALK TKIs show robust and durable disease-free survival benefit in non-small cell lung cancer
Data from the ELEVATE and ALINA studies highlight the gains provided by adjuvant ALK therapy in patients with ALK-positive disease
Novel treatment strategies investigated for thymic epithelial tumours lead to uncertain benefits
Rivoceranib after prior therapy and peri-operative pembrolizumab demonstrates promising efficacy but it is not superior to the current standard therapy
How therapeutically tractable is MUC1 as a tumour-associated antigen?
Early proof-of-concept is provided showing pan-tumour activity of a novel antibody–drug conjugate
Extensive-stage small-cell lung cancer: new approaches on the horizon?
Tarlatamab as first-line therapy and ceralasertib plus durvalumab as maintenance therapy have demonstrated potential efficacy and manageable tolerability
International collaboration and a shared vision are key to improving cancer patients’ lives
The 2025 ESMO Lifetime Achievement Awardee, Prof. Rolf Stahel, reflects on the role of the oncology community to drive progress in cancer care
Target-led treatments for lung cancer – are they moving to the next level?
Antibody–drug conjugates may represent a step up from existing therapeutic options, but further optimisation and biomarker analyses are required.
New evidence is reshaping second-line and maintenance treatment for small cell lung cancer
Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival
Perioperative durvalumab led to encouraging survival data in resectable NSCLC
An improvement was observed when immunotherapy was added to neoadjuvant chemotherapy, but further data are needed to confirm the survival benefit
Overall survival benefit achieved with amivantamab plus lazertinib in advanced EGFR-mutated NSCLC
Final results from the MARIPOSA trial provide further supporting evidence to the first-line treatment combination